Literature DB >> 6823136

The role of the activated clotting time in heparin administration and neutralization for cardiopulmonary bypass.

R A Esposito, A T Culliford, S B Colvin, S J Thomas, H Lackner, F C Spencer.   

Abstract

Precise guidelines for heparin administration and neutralization during cardiopulmonary bypass (CPB) are not established. To a large extent, the uncertainty originates from a disparity between the heparin dosage, the plasma heparin concentration, and the clinical heparin effect. We investigated these relationships in 44 consecutive patients at New York University Medical Center. Following serial loading doses of heparin (2 and 4 mg/kg) there was a wide variation in both the measured clinical heparin effect (activated clotting time--ACT) and the plasma heparin concentration. When the Act was compared to the heparin concentration, there was no linear relationship noted after heparin does commonly employed for CPB. The calculated heparin sensitivity varied over a fourfold range and was not related to the baseline antithrombin III activity. At the completion of CPB, heparin was neutralized with a 2 mg/kg protamine dose regardless of the total heparin dose. Heparin levels fell from 4.17 +/- 1.29 to 0.19 +/- 0.20 units/ml. Additional protamine was given to 49% of the patients as the ACT had not returned to pre-heparin levels. The total protamine dose rarely exceeded 3 mg/kg. This technique resulted in the administration of 30% to 50% less protamine than predicted by other commonly used protocols. In the subsequent 4 hours after protamine administration, heparin levels remained insignificant. Mild heparin rebound was found in two patients (4.5%) but was not associated with excessive bleeding. Following bypass a comparison of heparin levels and ACTs demonstrated the ACT to be a poor indicator of residual circulating heparin. These data show: (1) that neither the heparin dosage nor the plasma heparin concentration can accurately predict the magnitude of the clinical heparin effect in patients undergoing CPB and emphasize the importance of the ACT as the best available measurement of safe anticoagulation, (2) heparin "rebound" was not clinically significant, and (3) heparin was neutralized with 2 to 3 mg/kg protamine in virtually all patients, regardless of the total heparin dose.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6823136

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  7 in total

1.  All ACTs are not created equal.

Authors:  J J Ferguson
Journal:  Tex Heart Inst J       Date:  1992

Review 2.  The hemostatic defect of cardiopulmonary bypass.

Authors:  Matthew Dean Linden
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

3.  Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi.

Authors:  Peter Hellstern; Juergen Bach; Melanie Simon; Werner Saggau
Journal:  J Extra Corpor Technol       Date:  2007-06

4.  Clinical Experience with Routine Activated Coagulation Time Monitoring During Elective PTCA.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

5.  Activated Clotting Time as a Marker of Inflammation in Hospitalized Patients.

Authors:  Christos Papageorgiou; Andreas Synetos; Konstantinos Tampakis; Hector Anninos; Christos Kontogiannis; Alkistis Kapelouzou; Ioannis Kanakakis; Dimitrios Tousoulis; Ioannis Paraskevaidis; Konstantinos Toutouzas
Journal:  Clin Appl Thromb Hemost       Date:  2020 Jan-Dec       Impact factor: 2.389

6.  ACT Values after Neutralization Lower than Pre-heparinization ACT Leads to Lower Operative Times, Bleeding, and Post-Operative Transfusions in CABG Patients: an Observational Study.

Authors:  Weitie Wang; Yongwang Wang; Jinshan Wang; Rihao Xu; Junwu Chai; Wei Zhou; Honglei Chen; Fenlong Xue; Xiangrong Kong; Wang Kai
Journal:  Braz J Cardiovasc Surg       Date:  2018 Nov-Dec

Review 7.  Transfusion risks and transfusion-related pro-inflammatory responses.

Authors:  George John Despotis; Lini Zhang; Douglas M Lublin
Journal:  Hematol Oncol Clin North Am       Date:  2007-02       Impact factor: 3.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.